Related Experiment Videos
Abnormalities of the transforming growth factor-beta pathway in ocular melanoma
N Myatt1, P Aristodemou, M H Neale
1Department of Pathology, Institute of Ophthalmology, University ollege London, Bath Street, London EC1V 9EL, UK.
Abstract:
The majority of ocular melanomas occur in the uveal tract. Chemotherapy is generally ineffective and large tumours requiring enucleation have a greater than 50% mortality at 5 years. Monosomy for chromosome 3 is common in uveal melanoma and it is known that there is loss of responsiveness to transforming growth factor beta (TGFbeta) in melanoma cell lines. Since the gene for TGFbeta receptor II (TGFbetaR2) is located on chromosome 3p22, this study investigates the possibility that the TGFbeta pathway, and TGFbetaR2 in particular, might be involved in the pathogenesis of this rare eye tumour. To this end, the expression of molecules in the pathway has been examined by immunocytochemistry (TGFbeta, TGFbetaR2, SMAD2, SMAD3, SMAD4, and p27), backed up by a cell culture assay of TGFbeta-mediated growth suppression, RT-PCR for SMAD4, and loss of heterozygosity (LOH) on 3p22. There was LOH at 3p22 in 6/19 tumours and loss of TGFbetaR2 expression in 10/27 tumours. Immunohistochemistry for SMADs 2, 3, and 4 showed potential loss of signal transduction in 14/27 tumours. The results indicate abnormality of the TGFbeta pathway in 61% of tumours for which unequivocal results were obtained and suggest that abrogation of control of melanocyte growth by the TGFbeta pathway may be important in the formation of uveal melanoma.
Insights
Transforming growth factor beta (TGFbeta) pathway alterations are common in uveal melanoma, a rare eye cancer. Loss of TGFbeta receptor II (TGFbetaR2) and downstream signaling molecules suggest pathway dysregulation contributes to tumor development.
Area of Science:
- Ophthalmology
- Oncology
- Molecular Biology
Background:
- Uveal melanoma is a rare eye cancer with poor prognosis, often unresponsive to chemotherapy.
- Monosomy of chromosome 3 is frequent in uveal melanoma, correlating with reduced transforming growth factor beta (TGFbeta) responsiveness.
- The TGFbeta receptor II (TGFbetaR2) gene is located on chromosome 3p22, a region often affected in uveal melanoma.
Purpose of the Study:
- To investigate the role of the TGFbeta pathway, specifically TGFbetaR2, in the pathogenesis of uveal melanoma.
- To determine the frequency of alterations in TGFbeta pathway components in uveal melanoma tumors.
Main Methods:
- Immunocytochemistry was used to assess the expression of TGFbeta, TGFbetaR2, SMAD2, SMAD3, SMAD4, and p27.
- Cell culture assays evaluated TGFbeta-mediated growth suppression.
- Reverse transcription-polymerase chain reaction (RT-PCR) analyzed SMAD4 expression.
- Loss of heterozygosity (LOH) analysis was performed on chromosome 3p22.
Main Results:
- Loss of heterozygosity at 3p22 was observed in 6 out of 19 tumors.
- Reduced TGFbetaR2 expression was detected in 10 out of 27 tumors.
- Potential loss of signal transduction through SMADs 2, 3, and 4 occurred in 14 out of 27 tumors.
- Aberrations in the TGFbeta pathway were identified in 61% of the analyzed tumors.
Conclusions:
- The TGFbeta pathway is frequently altered in uveal melanoma.
- Dysregulation of the TGFbeta pathway, including loss of TGFbetaR2, may be crucial in the development of uveal melanoma.
- Impaired TGFbeta-mediated control of melanocyte growth is implicated in this rare eye tumor's formation.